Elise Alspach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elise Alspach has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Maureen J. Donlin
Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri, USA
25 shared publications - Katey S. Hunt
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri
18 shared publications - Ryan M. Teague
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri
18 shared publications - Michelle Brennan
Department of Biochemistry, Saint Louis University School of Medicine, St. Louis, Missouri
17 shared publications - Sheila A. Stewart
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, USA
17 shared publications - Alexander Piening
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri
16 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 3: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC from Liu et al.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 3: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC from Liu et al.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 4: TCR repertoire analysis reveals sex-based differences in the association between T cell clonal expansion and expression of CXCL13.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 4: TCR repertoire analysis reveals sex-based differences in the association between T cell clonal expansion and expression of CXCL13.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 2: Sex-based differences in CXCL13 expression level and frequency of CXCL13+ T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 2: Sex-based differences in CXCL13 expression level and frequency of CXCL13+ T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 1: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 1: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Emerging evidence in preclinical models demonstrates that antitumor immunity is not equivalent between males and females. However, more investigation in patients and across a wider range of cancer types is needed to fully understand sex as a variable in tumor immune responses. We investigated differences in T-cell responses between male and female patients with lung cancer by performing sex-based analysis of single cell transcriptomic datasets. We found that the transcript encoding CXC motif chemokine ligand 13 (CXCL13), which has recently been shown to correlate with T-cell tumor specificity, is expressed at greater levels in T cells isolated from female compared with male patients. Furthermore, increased CXCL13 expression was associated with response to PD1–targeting immunotherapy in female but not male patients. These findings suggest that there are sex-based differences in T-cell function required for response to anti–PD1 therapy in lung cancer that may need to be considered during patient treatment decisions.See related Spotlight by Cruz-Hinojoza and Stromnes, p. 952
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Emerging evidence in preclinical models demonstrates that antitumor immunity is not equivalent between males and females. However, more investigation in patients and across a wider range of cancer types is needed to fully understand sex as a variable in tumor immune responses. We investigated differences in T-cell responses between male and female patients with lung cancer by performing sex-based analysis of single cell transcriptomic datasets. We found that the transcript encoding CXC motif chemokine ligand 13 (CXCL13), which has recently been shown to correlate with T-cell tumor specificity, is expressed at greater levels in T cells isolated from female compared with male patients. Furthermore, increased CXCL13 expression was associated with response to PD1–targeting immunotherapy in female but not male patients. These findings suggest that there are sex-based differences in T-cell function required for response to anti–PD1 therapy in lung cancer that may need to be considered during patient treatment decisions.See related Spotlight by Cruz-Hinojoza and Stromnes, p. 952
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L–CD40 Pathway
Sex-based differences in cancer incidence are incompletely understood, but potential roles for the immune system are beginning to emerge. CD4+ T cells play a central role in coordinating antitumor immunity. In addition to cytokine production, CD40L expression on CD4+ T cells provides necessary helper signaling to dendritic cells (DC) that is required for the priming of cytotoxic tumor-specific CD8+ T cells. Despite these critical functions, the impact of biological sex on the CD4+ T-cell response to cancer remains unknown. In this study, we demonstrate that impaired immune-mediated tumor control in male mice compared with female mice is driven by disparate CD4+ T-cell responses in a mouse model of bladder cancer. We found that CD40L expression was reduced on CD4+ T cells isolated from males via a mechanism predominantly driven by cell-intrinsic androgen receptor signaling, resulting in decreased DC licensing through CD40 within tumor-draining lymph nodes. These deficits resulted in decreased helper CD4+ T-cell frequencies and impaired CD8+ T-cell function within the male tumor microenvironment, which could be rescued by targeting the CD40L–CD40 axis. Our findings identify a novel mechanism of CD4+ T cell–based sex differences in the immune response to cancer that impairs tumor control.
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L–CD40 Pathway
Sex-based differences in cancer incidence are incompletely understood, but potential roles for the immune system are beginning to emerge. CD4+ T cells play a central role in coordinating antitumor immunity. In addition to cytokine production, CD40L expression on CD4+ T cells provides necessary helper signaling to dendritic cells (DC) that is required for the priming of cytotoxic tumor-specific CD8+ T cells. Despite these critical functions, the impact of biological sex on the CD4+ T-cell response to cancer remains unknown. In this study, we demonstrate that impaired immune-mediated tumor control in male mice compared with female mice is driven by disparate CD4+ T-cell responses in a mouse model of bladder cancer. We found that CD40L expression was reduced on CD4+ T cells isolated from males via a mechanism predominantly driven by cell-intrinsic androgen receptor signaling, resulting in decreased DC licensing through CD40 within tumor-draining lymph nodes. These deficits resulted in decreased helper CD4+ T-cell frequencies and impaired CD8+ T-cell function within the male tumor microenvironment, which could be rescued by targeting the CD40L–CD40 axis. Our findings identify a novel mechanism of CD4+ T cell–based sex differences in the immune response to cancer that impairs tumor control.
- Open Access
- 14 August 2025
- Published by Springer Nature in Research Square
Impaired CD4+ T cell help through the CD40L-CD40 pathway contributes to reduced tumor control in males
Sex-based differences in cancer incidence are incompletely understood, but potential roles for the immune system are beginning to emerge. CD4+ T cells play a central role in organizing antitumor immunity. In addition to cytokine production, CD40L expression on CD4+ T cell provides necessary helper signaling to dendritic cells that is required for the priming of cytotoxic tumor-specific CD8+ T cells. Despite these critical functions, the impact of biological sex on the CD4+ T cell response to cancer remains unknown. Here, we demonstrate that impaired immune-mediated tumor control in male compared to female mice is driven by disparate helper CD4+ T cell responses between the sexes. We find that CD40L expression is reduced on CD4+ T cells isolated from males via a mechanism predominantly driven by sex hormones, resulting in decreased CD40 signaling in dendritic cells within tumor-draining lymph nodes. These deficits resulted in decreased helper CD4+ T cell frequencies and impaired CD8+ T cell function within the male tumor microenvironment which could be rescued by targeting the CD40L-CD40 axis. Our findings identify a novel mechanism of CD4+ T cell-based sex differences in the immune response to cancer that impairs tumor control. *Stephen T. Ferris & Elise Alspach are co-senior authors.
- 14 August 2025
- Published by Springer Nature in Research Square
Open AccessImpaired CD4+ T cell help through the CD40L-CD40 pathway contributes to reduced tumor control in males
Sex-based differences in cancer incidence are incompletely understood, but potential roles for the immune system are beginning to emerge. CD4+ T cells play a central role in organizing antitumor immunity. In addition to cytokine production, CD40L expression on CD4+ T cell provides necessary helper signaling to dendritic cells that is required for the priming of cytotoxic tumor-specific CD8+ T cells. Despite these critical functions, the impact of biological sex on the CD4+ T cell response to cancer remains unknown. Here, we demonstrate that impaired immune-mediated tumor control in male compared to female mice is driven by disparate helper CD4+ T cell responses between the sexes. We find that CD40L expression is reduced on CD4+ T cells isolated from males via a mechanism predominantly driven by sex hormones, resulting in decreased CD40 signaling in dendritic cells within tumor-draining lymph nodes. These deficits resulted in decreased helper CD4+ T cell frequencies and impaired CD8+ T cell function within the male tumor microenvironment which could be rescued by targeting the CD40L-CD40 axis. Our findings identify a novel mechanism of CD4+ T cell-based sex differences in the immune response to cancer that impairs tumor control. *Stephen T. Ferris & Elise Alspach are co-senior authors.
- Open Access
- 18 June 2025
- Published by Springer Nature in Research Square
Type I Interferon Restricts mRNA Vaccine Efficacy Through Suppression of Antigen Uptake in cDCs
Type I interferons (IFNs) are key mediators of innate immune activation, promoting upregulation of costimulatory molecules and Major Histocompatibility Complex (MHC) I/II on antigen presenting cells (APCs). However, IFNs also suppress endogenous transcription and translation to restrict viral replication. Critically, IFN-stimulated APCs lose the capacity to acquire new antigens, making the timing of IFN signaling a crucial determinant of vaccine efficacy. Here, we show that both DC-specific loss of IFNα/β receptor (IFNαR) and transient blockade of IFNαR before vaccination enhances vaccine uptake and expression within DCs, improves CD8⁺ T cell priming, and leads to superior tumor control. We also demonstrate that IFN signaling before vaccination, triggered by prior infection or administration of a different vaccine, impairs dendritic cell uptake of mRNA-LNP vaccines and reduces the magnitude of vaccine-specific CD8⁺ T cell responses. These findings highlight the dual-edged nature of IFN signaling and offer a potential strategy for enhancing vaccine-induced immunity.
- 18 June 2025
- Published by Springer Nature in Research Square
Open AccessType I Interferon Restricts mRNA Vaccine Efficacy Through Suppression of Antigen Uptake in cDCs
Type I interferons (IFNs) are key mediators of innate immune activation, promoting upregulation of costimulatory molecules and Major Histocompatibility Complex (MHC) I/II on antigen presenting cells (APCs). However, IFNs also suppress endogenous transcription and translation to restrict viral replication. Critically, IFN-stimulated APCs lose the capacity to acquire new antigens, making the timing of IFN signaling a crucial determinant of vaccine efficacy. Here, we show that both DC-specific loss of IFNα/β receptor (IFNαR) and transient blockade of IFNαR before vaccination enhances vaccine uptake and expression within DCs, improves CD8⁺ T cell priming, and leads to superior tumor control. We also demonstrate that IFN signaling before vaccination, triggered by prior infection or administration of a different vaccine, impairs dendritic cell uptake of mRNA-LNP vaccines and reduces the magnitude of vaccine-specific CD8⁺ T cell responses. These findings highlight the dual-edged nature of IFN signaling and offer a potential strategy for enhancing vaccine-induced immunity.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 1: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 1: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 2: Sex-based differences in CXCL13 expression level and frequency of CXCL13+ T cells.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 2: Sex-based differences in CXCL13 expression level and frequency of CXCL13+ T cells.